A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

The New England Journal of Medicine
Chris H PolmanAFFIRM Investigators

Abstract

Natalizumab is the first alpha4 integrin antagonist in a new class of selective adhesion-molecule inhibitors. We report the results of a two-year phase 3 trial of natalizumab in patients with relapsing multiple sclerosis. Of a total of 942 patients, 627 were randomly assigned to receive natalizumab (at a dose of 300 mg) and 315 to receive placebo by intravenous infusion every four weeks for more than two years. The primary end points were the rate of clinical relapse at one year and the rate of sustained progression of disability, as measured by the Expanded Disability Status Scale, at two years. Natalizumab reduced the risk of sustained progression of disability by 42 percent over two years (hazard ratio, 0.58; 95 percent confidence interval, 0.43 to 0.77; P<0.001). The cumulative probability of progression (on the basis of Kaplan-Meier analysis) was 17 percent in the natalizumab group and 29 percent in the placebo group. Natalizumab reduced the rate of clinical relapse at one year by 68 percent (P<0.001) and led to an 83 percent reduction in the accumulation of new or enlarging hyperintense lesions, as detected by T2-weighted magnetic resonance imaging (MRI), over two years (mean numbers of lesions, 1.9 with natalizumab and 1...Continue Reading

References

Nov 1, 1994·The Journal of Clinical Investigation·R R Lobb, M E Hemler
Jan 1, 1993·The Journal of Experimental Medicine·J L BaronC A Janeway
Jan 29, 1994·Lancet·C Ffrench-Constant
Mar 29, 2002·Annals of Neurology·Roy W BeckAlfred W Sandrock
Jan 3, 2003·The New England Journal of Medicine·David H MillerUNKNOWN International Natalizumab Multiple Sclerosis Trial Group
Jun 11, 2005·The New England Journal of Medicine·Annette Langer-GouldDaniel Pelletier
Jun 11, 2005·The New England Journal of Medicine·B K Kleinschmidt-DeMasters, Kenneth L Tyler
Jun 11, 2005·The New England Journal of Medicine·Gert Van AsschePaul Rutgeerts
Mar 3, 2006·The New England Journal of Medicine·Richard A RudickUNKNOWN SENTINEL Investigators
Mar 3, 2006·The New England Journal of Medicine·Tarek A YousryDavid B Clifford

❮ Previous
Next ❯

Citations

Jul 14, 2010·Archives of Neurology·Olaf StüveTodd N Eagar
Mar 9, 2007·Inflammatory Bowel Diseases·Alessandro LavagnaAngelo Pera
Sep 18, 2010·Inflammatory Bowel Diseases·Caihong WangRodney D Newberry
Jun 29, 2011·Inflammatory Bowel Diseases·Alice LaroniGiovanni Luigi Mancardi
Apr 21, 2007·Current Treatment Options in Neurology·Adrienne Boissy, Robert J Fox
Aug 3, 2010·Archivum Immunologiae Et Therapiae Experimentalis·Jin NakaharaNorihiro Suzuki
Jan 16, 2008·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·C Infante-DuarteF Zipp
Dec 1, 2006·Der Nervenarzt·Peter Rieckmann, Peter Rieckmann
Apr 26, 2008·Der Nervenarzt·A HaghikiaR Gold
Sep 23, 2008·Der Nervenarzt·R A Linker, B C Kieseier
Mar 17, 2010·Der Nervenarzt·M Buttmann, H Wiendl
Oct 20, 2009·European Journal of Clinical Pharmacology·Carlo PiccinniNicola Montanaro
Mar 1, 2012·European Journal of Clinical Pharmacology·Maria Pia Sormani, Alessio Signori
Sep 18, 2012·European Journal of Clinical Pharmacology·Silvio GarattiniRita Banzi
Mar 13, 2012·Acta Neuropathologica·Jeffrey SchowinskyB K Kleinschmidt-DeMasters
Aug 13, 2013·Acta Neuropathologica·Daniel E LowtherDaniel M Altmann
Nov 16, 2007·Journal of Neurology·Christoph KleinschnitzHeinz Wiendl
Nov 14, 2008·Journal of Neurology·UNKNOWN Multiple Sclerosis Therapy Consensus Group (MSTCG)R Hohlfeld
Jun 19, 2008·Journal of Neurology·Charlotte YtterbergLena von Koch
Apr 9, 2008·Journal of Neurology·Ralf Gold
Mar 28, 2009·Journal of Neurology·P S RommerU K Zettl
Mar 28, 2009·Journal of Neurology·Olaf StüveBernd C Kieseier
Mar 25, 2009·Journal of Neurology·Michael HutchinsonUNKNOWN AFFIRM and SENTINEL Investigators
Jul 18, 2009·Journal of Neurology·Azza IsmailBasil Sharrack
Jan 7, 2010·Journal of Neurology·Saud A SadiqEdward W A Brydon
Feb 5, 2011·Journal of Neurology·Christine LebrunMarc Frenay
Mar 26, 2011·Journal of Neurology·Martin DuddyRalf Gold
Jun 4, 2011·Journal of Neurology·Dorothea Buck, Bernhard Hemmer
Jun 8, 2011·Journal of Neurology·Kerstin Hellwig, Ralf Gold
Oct 20, 2011·Journal of Neurology·Bianca Weinstock-GuttmanChristophe Hotermans
Dec 22, 2011·Journal of Neurology·Malou H J FanchampsOzgür Yaldizli
Sep 1, 2012·Journal of Neurology·Peter RieckmannSven Schippling

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.